Skip to main content

Advertisement

SpringerLink
Log in

The world health organization—International society of hypertension blood pressure lowering treatment trialists’ collaboration: Prospective collaborative overviews of major randomized trials of blood pressure-lowering treatments

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Clear evidence shows that decreasing blood pressure reduces risks for major cardiovascular events in patients with hypertension. However, there is considerable uncertainty about the separate effects of the various classes of blood pressure-lowering agents and the effects of blood pressure lowering in patients at high risk, particularly in the absence of hypertension. Several new randomized controlled trials have been started in the past few years in an effort to address these questions. However, individually, these studies are unlikely to resolve all current uncertainties. For this reason, systematic overviews and meta-analyses of the major ongoing trials are planned. The overviews will be conducted as a collaboration among the principal investigators of the participating trials and will involve about 270,000 patients and 1.1 million patientyears of follow-up. The combined trial results should provide good statistical power to detect even modest differences in the effects of various treatments on major cardiovascular outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. MacMahon S, Peto R, Cutler J, et al.: Blood pressure, stroke, and coronary heart disease. Part I, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990, 335:765–774.

    Article  PubMed  CAS  Google Scholar 

  2. Prospective Studies Collaboration: Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 45,000 people in 45 prospective cohorts. Lancet 1995, 346:1647–1653.

    Article  Google Scholar 

  3. Eastern Stroke and Coronary Heart Disease Collaborative Research Group: Blood pressure, cholesterol and stroke in eastern Asia. Lancet 1998, 352:1801–1807.

    Article  Google Scholar 

  4. Kannel WB, Castelli WP, McNamara PM, et al.: Role of blood pressure in the development of congestive heart failure. N Engl J Med 1972, 287:781–787.

    Article  PubMed  CAS  Google Scholar 

  5. Klag MJ, Whelton PK, Randall BL, et al.: Blood pressure and end-stage renal disease in men. N Engl J Med 1996, 334:13–18.

    Article  PubMed  CAS  Google Scholar 

  6. Rodgers A, MacMahon S, Gamble G, et al.: Blood pressure and risk of stroke in patients with cerebrovascular disease. Br Med J 1996, 313:147.

    CAS  Google Scholar 

  7. Flack J, Neaton J, Grimm R, et al.: Blood pressure and mortality among men with prior myocardial infarction. Circulation; J Am Heart Assoc 1995, 92:2437–2445.

    CAS  Google Scholar 

  8. MacMahon S, Neal B, Rodgers A: Blood pressure lowering for the primary and secondary prevention of coronary and cerebrovascular disease. Schweiz Med Wochenschr 1995, 125:2479–2486.

    PubMed  CAS  Google Scholar 

  9. MacMahon S, Rodgers A: The effects of antihypertensive treatment on vascular disease: reappraisal of the evidence in 1993. J Vasc Med Biol 1993, 4:265–271.

    Google Scholar 

  10. Collins R, Peto R, MacMahon S, et al.: Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990, 335:827–839.

    Article  PubMed  CAS  Google Scholar 

  11. Collins R, MacMahon S: Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994, 50:272–298.

    PubMed  CAS  Google Scholar 

  12. Kostis J, Davis B, Cutler J, et al.: Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension (ISH). SHEP Cooperative Research Group. JAMA 1997, 278:212–216.

    Article  PubMed  CAS  Google Scholar 

  13. Yusuf S, Thomas T, Abbott RD: Changes in hypertension treatment and in congestive heart failure mortality in the United States. Hypertension 1989, 13:74–79.

    Google Scholar 

  14. Medical Research Council Working Party: MRC Trial of treatment of mild hypertension. Principal results. Br Med J 1985, 291:97–104.

    Google Scholar 

  15. Medical Research Council Working Party: Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992, 304:405–412.

    Google Scholar 

  16. The IPPPSH Collaborative Group: Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blocker oxprenolol: the international prospective primary prevention study in hypertension (IPPPSH). J Hypertens 1985, 3:379–392.

    Article  Google Scholar 

  17. Wilhelmsen L, Berglund G, Elmfeld D: Beta-blockers versus diuretics in hypertensive men. Main results from the HAPPHY trial. J Hypertens 1987, 5:561–576.

    Article  PubMed  CAS  Google Scholar 

  18. Yusuf S, Peto R, Lewis J, et al.: Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985, 27:335–371.

    Article  PubMed  CAS  Google Scholar 

  19. Doughty RN, Rodgers A, Sharpe N, et al.: Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomised controlled trials. Eur Heart J 1997, 18:560–565.

    PubMed  CAS  Google Scholar 

  20. Hansson L, Lindholm L, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Projec (CAPPP) randomised trial. Lancet 1999, 353:611–616. This is the first trial to report the comparative effects of treatment with ACE inhibitor-based compared to diuretic or beta-blocker-based blood pressure lowering agents, on major cardiovascular outcomes. The investigators reported fewer new cases of diabetes, but more strokes in the captopril treated group. It is possible, however, that irregularities in the assignment of treatment, together with the unblinded study design, could have influenced the findings.

    Article  PubMed  CAS  Google Scholar 

  21. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998, 317:713–720. This study, conducted among diabetic patients with hypertension, was the first to report the comparative effects of ACE-inhibitor-based therapy compared to beta-blocker-based treatment. The absence of any detectable difference between the two treatment regimens, on either microvascular or macrovascular complications of diabetes, suggests that the principal benefit from such treatment may result from blood pressure lowering per se rather than from specific properties of different classes of drug.

    Google Scholar 

  22. Pahor M: The fosinopril amlodipine cardiovascular events trial (FACET) and new evidence on antihypertensive treatments in diabetics. Am J Hypertens 1998, 11:245A.

    Article  Google Scholar 

  23. Estacio R, Jeffers B, Hiatt W, et al.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependant diabetes and hypertension. N Engl J Med 1998, 338:645–652.

    Article  PubMed  CAS  Google Scholar 

  24. Garg R, Yusuf S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995, 273:1450–1456.

    Article  PubMed  CAS  Google Scholar 

  25. Lonn EM, Yusuf S, Jha P, et al.: Emerging role of angiotensinconverting enzyme inhibitors in cardiac and vascular protection. Circulation 1994, 90:2056–2067.

    PubMed  CAS  Google Scholar 

  26. Lewis EJ, Hunsicker LG, Bain RP, et al.: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456–1462.

    Article  PubMed  CAS  Google Scholar 

  27. Staessen J, Fagard R, Thijs L, et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997, 350:757–764. This was the first trial to provide definitive evidence of beneficial effects of calcium antagonist-based blood pressure lowering therapy on major cardiovascular outcomes. Among patients with systolic hypertension, active treatment was associated with a significant reduction in the risk of stroke.

    Article  PubMed  CAS  Google Scholar 

  28. Liu L, Gong L, Wang J, et al.: Stroke incidence in the placebo controlled chinese trial on isolated systolic hypertensio in the elderly [abstract]. Am J Hypertens 1998, 11(part 2):245A.

    Google Scholar 

  29. Gong L, Zhang W, Zhu Y, et al.: Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996, 14:1237–1245.

    Article  PubMed  CAS  Google Scholar 

  30. Held P, Yusuf S, Furberg C: Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. Br Med J 1989, 229:1187–1192.

    Google Scholar 

  31. Yusuf S, Held P, Furberg C: Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991, 67:1295–1297.

    Article  PubMed  CAS  Google Scholar 

  32. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension: Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens 1997, 15:105–115. This report was prepared in response to concerns about possible harmful effects of calcium antagonists on the risk of coronary death, cancer and non-cerebral haemorrhage. The report clearly identifies the problems of non-randomised methodologies for the investigation of treatment effects, and highlights the need for evidence from large scale randomised trials to guide treatment decisions.

    Google Scholar 

  33. Cohn J, Ziesche S, Loss L. et al.: Effect of felodipine on shortterm exercise and neurohormone and long-term mortality in heart failure: results of V-Heft III. Circulation 1995, 92:1–43.

    Google Scholar 

  34. Packer M, O’Connor C, Ghali J, et al.: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996, 335:1107–1114.

    Article  PubMed  CAS  Google Scholar 

  35. Hansson L, Zanchetti A, Carruthers S, et al.: Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998, 351:1755–1762. This large trial randomised hypertensive patients to one of three target blood pressure levels-80mmHg, 85mmHg, or 90mmHg-with the aim of comparing the effects of more intensive and less intensive blood pressure lowering. The differences between the blood pressure levels achieved in the three groups were smaller than planned, and there were too few events recorded to reliably determine the most likely effects of the blood pressure differences achieved. However, in the subgroup with diabetes, more intensive blood pressure lowering was associated with reduced risks of cardiovascular events.

    Article  PubMed  CAS  Google Scholar 

  36. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998, 317:703–713. This study, conducted among diabetic patients with hypertension, demonstrated that tight blood pressure control (target BP < 150/85) resulted in greater benefits than less tight control (target BP < 180/105). Tight blood pressure control was associated with significantly fewer strokes, and a trend towards fewer myocardial infarctions as well as with significantly fewer microvascular complications of diabetes.

    Google Scholar 

  37. World Health Organisation-International Society of Hypertension Blood Pressure Lowering Treatment Trialists’ Collaboration: Protocol for prospective collaborative overviews of major randomized trials of blood-pressure lowering treatments. J Hypertens 1998, 16:127–137. This paper provides detailed plans for collaborative systematic overviews of large scale randomised trials of antihypertensive agents. When completed, the results of these overviews should provide more reliable evidence than will any of the individual trials alone.

    Google Scholar 

  38. Collins R, Gray R, Godwin J, et al.: Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Stat Med 1987, 6:245–250.

    Article  PubMed  CAS  Google Scholar 

  39. Antiplatelet Trialists’ Collaboration: Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994, 308:81–106.

    Google Scholar 

  40. Antiplatelet Trialists Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. III: Reduction in venous thrombosis and pulmonary embolism by antiplatele prophylaxis among surgical and medical patients. Br Med J 1994, 308:235–246.

    Google Scholar 

  41. Antiplatelet Trialists Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br Med J 1994, 308:159–168.

    Google Scholar 

  42. Early Breast Cancer Trialists’ Collaborative Group: Treatment of early breast cancer. In Vol. 1: Worldwide evidence 1985–1990., New York: Oxford University Press; 1990.

    Google Scholar 

  43. Early Breast Cancer Trialists’ Collaborative Group: Systematic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992, 339:1–15, 71–85.

    Google Scholar 

  44. Cholesterol Treatment Trialists’ (CTT) Collaboration: Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Am J Cardiol 1995, 75:1130–1134.

    Article  Google Scholar 

  45. Schrier RW, Savage S: Appropriate blood pressure control in type II diabetes (ABCD trial): implications for complications. Am J Kidney Dis 1992, 20:653–657.

    PubMed  CAS  Google Scholar 

  46. Lubsen J, Poole-Wilson P: ACTION: A 30,000 patient-years double-blind, placebo-controlled trial of nifedipine GITS in stable angina. Br J Clin Pract 1997, 51(suppl 88):23–26.

    Google Scholar 

  47. Davis BR, Cutler JA, Gordon DJ, et al.: Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996, 9:342–360.

    Article  PubMed  CAS  Google Scholar 

  48. Management Committee on behalf of the High Blood Pressure Research Council of Australia: Australian comparative outcome trial of angiotensin converting enzyme inhibitor- and diuretic-based treatment of hypertension in the elderly (ANBP2): objectives and protocol. Clin Exp Pharmacol Physiol 1997, 24:188–192.

    Google Scholar 

  49. Zanchetti A: Prevalence of carotid atherosclerosis in hypertension: preliminary data from the European Lacidipine Study on Atherosclerosis. Blood Press 1996, 5(suppl 4):30–35.

    Google Scholar 

  50. The HOPE Study Investigators: The HOPE (Heart Outcome Prevention Evaluation) Study: the design of a large, simple randomised trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996, 12:127–137.

    Google Scholar 

  51. Bulpitt C, Fletcher A, Amery A, et al.: The hypertension in the very elderly trial (HYVET). Drugs Aging 1994, 5:171–183.

    Article  PubMed  CAS  Google Scholar 

  52. Brown M, Castaigne A, Ruilope LM, et al.: INSIGHT-international nifedipine GITS study intervention as a goal in hypertension treatment. J Human Hypertens 1996, 10(Suppl 3):157S-160S.

    Google Scholar 

  53. Pepine C, Handberg-Thurmond E, Marks R, et al.: Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): and Internet-based randomised trial in coronary artery disease patients with hypertension. J Am Coll Cardiol 1998, 32:1228–1237.

    Article  PubMed  CAS  Google Scholar 

  54. Dahlof B, Devereux R, de Faire U, et al.: The Losartan Intervention For Endpoint Reduction (LIFE) in Hypertension Study. Rationale, design, and methods. J Hypertens 1997, 10:705–713.

    Article  CAS  Google Scholar 

  55. Kuramoto K: Treatment of elderly hypertensives in Japan: national intervention co-operative study in elderly hypertensives. J Hypertens 1994, 12(suppl 6):S35-S40.

    CAS  Google Scholar 

  56. The NORDIL Group: The Nordic diltiazem study (NORDIL). A prospective intervention trial of calcium antagonis therapy in hypertension. Blood Press 1993, 2:312–321.

    Google Scholar 

  57. The PHYLLIS Project Group: Plaque hypertension lipidlowering Italian study (PHYLLIS): a protocol for noninvasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive patients. J Hypertens 1993, 11(suppl 5):S314-S315.

    Google Scholar 

  58. PROGRESS Management Committee: Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS. J Hypertens 1996, 14(suppl 2):S41-S46.

    Google Scholar 

  59. Lees R, Pitt B, Chan R, et al.: Baseline clinical and angiographic data in the Quinapril Ischaemic Event Trial (QUIET). Am J Cardiol 1996, 78:1011–1016.

    Article  PubMed  CAS  Google Scholar 

  60. Teo K, Burton J, Buller C, et al.: Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Can J Cardiol 1997, 13(suppl 6):591–599.

    PubMed  CAS  Google Scholar 

  61. Hansson L, Group FTS: Study on cognition and prognosis in the elderly (SCOPE). Design and objectives. J Hypertens 1998, 16(suppl 2):246.

    Google Scholar 

  62. Malacco E, Gnemmi A, Romagnoli A, et al.: Systolic hypertension in the elderly: long-term lacidipine treatment. J Cardiovasc Pharmacol 1994, 23(suppl 5):S62-S66.

    PubMed  CAS  Google Scholar 

  63. Dahlof B, Hansson L, Lindholm L, et al.: STOP-Hypertension-2: A prospective intervention trial of ‘newer’ vesus ‘older’ treatment alternatives in old patients with hypertension. Blood Press 1993, 2:136–141.

    PubMed  CAS  Google Scholar 

  64. Zanchetti A, Magnani B, Dal Palu C, et al.: Atherosclerosis and calcium antagonists: the VHAS. J Human Hypertens 1992, 6(suppl 2):S45-S48.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for International Health, The University of Sydney, Crows Nest, PO Box 1225, 1585, Sydney, NSW, Australia

    Bruce Neal MBCLB, MRCP & Stephen MacMahon PhD, MPH, FACC

Authors
  1. Bruce Neal MBCLB, MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen MacMahon PhD, MPH, FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neal, B., MacMahon, S. The world health organization—International society of hypertension blood pressure lowering treatment trialists’ collaboration: Prospective collaborative overviews of major randomized trials of blood pressure-lowering treatments. Current Science Inc 1, 346–356 (1999). https://doi.org/10.1007/s11906-999-0045-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-999-0045-2

Keywords

Search

Navigation